Form 4: BioLargo Director Receives Stock Options as Compensation for Board Service
SEC Form 4 Filing
Christina Elaine Bray, a director at BioLargo, Inc., received stock options as compensation for her board service during the most recent quarterly period.
Summary
- On September 30, 2024, Christina Elaine Bray, a director of BioLargo, Inc., was granted an option to purchase 81,522 shares of common stock at an exercise price of $0.23 per share.
- These options were issued as payment for $18,750 in fees for her service on the board of directors for the most recently completed quarterly period, according to the company's 2024 Equity Incentive Plan.
- Following this transaction, Ms. Bray directly owns options to purchase 794,333 shares of BioLargo common stock.
- A Limited Power of Attorney was granted to John R. Browning on November 1, 2022, to execute and file Section 16 reports on behalf of Christina Bray.
Sentiment
Score: 6
Explanation: Neutral sentiment as it reports a routine transaction of director compensation. The use of stock options can be seen as a positive for cash conservation, but also dilutive to existing shareholders.
Positives
- The issuance of stock options aligns the director's interests with those of the shareholders.
- The compensation structure helps conserve cash for the company.
Future Outlook
NA
Industry Context
Stock options are a common form of compensation for directors, especially in smaller companies, to align their interests with shareholders and conserve cash.
Comparison to Industry Standards
- Director compensation packages vary widely based on company size, industry, and performance.
- Stock options are a typical component, often benchmarked against peer companies to ensure competitiveness.
- Comparing BioLargo's director compensation to similar companies in the cleantech or environmental technology sectors would provide a more detailed assessment.
Related Party Transactions
- The grant of stock options to Christina Bray, a director, is a related party transaction.
Stakeholder Impact
- Shareholders may experience dilution due to the issuance of new stock options.
- The company benefits from conserving cash by using equity-based compensation.
Key Dates
| Date | Description |
|---|---|
| 2022-11-01 | Limited Power of Attorney granted to John R. Browning. |
| 2024-09-30 | Date of the transaction: Christina Bray received stock options. |
| 2024-09-30 | Options exercisable date. |
| 2024-10-02 | Date of the Form 4 filing. |
| 2034-09-30 | Options expiration date. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.